QSAR of Human Factor Xa Inhibitor N2-Aroylanthranilamides Using Principal Component Factor Analysis

Author： Roy Kunal   De A. U.   Sengupta Chandana  

Publisher： Taylor & Francis Ltd

ISSN： 1055-9612

Source： Drug Design and Discovery, Vol.18, Iss.1, 2002-03, pp. : 23-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

QSAR With Electrotopological State Atom Index: Human Factor Xa Inhibitor N2-Aroylanthranilamides

By Roy Kunal   De A. U.   Sengupta Chandana  

Drug Design and Discovery, Vol. 18, Iss. 1, 2002-03 ,pp. : 33-43

Taylor & Francis Ltd

Access to resources Recommend Favorite

Kinetic Characterization of Factor Xa Binding Using a Quenched Fluorescent Substrate Based on the Reactive Site of Factor Xa Inhibitor from Bauhinia ungulata Seeds

By  

Current Medicinal Chemistry, Vol. 10, Iss. 13, 2003-07 ,pp. : 1085-1093

Bentham Science Publishers

Access to resources Recommend Favorite

Edoxaban: A New Oral Direct Factor Xa Inhibitor

By Camm A. John  

Drugs, Vol. 71, Iss. 12, 2011-08 ,pp. : 1503-1526

Adis International

Access to resources Recommend Favorite

Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy

By Turpie Alexander GG  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1373-1384

Informa Healthcare

Access to resources Recommend Favorite

Rivaroxaban, the first oral, direct factor Xa inhibitor

By Fassiadis Nicholas  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 18, 2009-12 ,pp. : 2945-2946

Informa Healthcare

Access to resources Recommend Favorite